395 related articles for article (PubMed ID: 10161371)
1. Filgrastim. A reappraisal of pharmacoeconomic considerations in the prophylaxis and treatment of chemotherapy-induced neutropenia.
Frampton JE; Faulds D
Pharmacoeconomics; 1996 Jan; 9(1):76-96. PubMed ID: 10161371
[TBL] [Abstract][Full Text] [Related]
2. Filgrastim. A review of its pharmacological properties and therapeutic efficacy in neutropenia.
Frampton JE; Lee CR; Faulds D
Drugs; 1994 Nov; 48(5):731-60. PubMed ID: 7530630
[TBL] [Abstract][Full Text] [Related]
3. Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings.
Frampton JE; Yarker YE; Goa KL
Drugs; 1995 May; 49(5):767-93. PubMed ID: 7541335
[TBL] [Abstract][Full Text] [Related]
4. Colony-stimulating factors for the management of neutropenia in cancer patients.
Dale DC
Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
[TBL] [Abstract][Full Text] [Related]
5. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF): an appraisal of its pharmacoeconomic status in neutropenia associated with chemotherapy and autologous bone marrow transplant.
Goa KL; Bryson HM
Pharmacoeconomics; 1994 Jan; 5(1):56-77. PubMed ID: 10146867
[TBL] [Abstract][Full Text] [Related]
6. A novel approach to maintain planned dose chemotherapy on time: a decision-making tool to improve patient care.
Lyman GH
Eur J Cancer; 2000 Apr; 36 Suppl 1():S15-21. PubMed ID: 10785605
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluations of granulocyte colony-stimulating factor: in the prevention and treatment of chemotherapy-induced neutropenia.
Esser M; Brunner H
Pharmacoeconomics; 2003; 21(18):1295-313. PubMed ID: 14750898
[TBL] [Abstract][Full Text] [Related]
8. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany].
Sehouli J; Goertz A; Steinle T; Dubois R; Plesnila-Frank C; Lalla A; von Minckwitz G
Dtsch Med Wochenschr; 2010 Mar; 135(9):385-9. PubMed ID: 20180162
[TBL] [Abstract][Full Text] [Related]
9. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
Bhana N
Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
Lathia N; Isogai PK; De Angelis C; Smith TJ; Cheung M; Mittmann N; Hoch JS; Walker S
J Natl Cancer Inst; 2013 Aug; 105(15):1078-85. PubMed ID: 23873405
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.
Cosler LE; Eldar-Lissai A; Culakova E; Kuderer NM; Dale D; Crawford J; Lyman GH
Pharmacoeconomics; 2007; 25(4):343-51. PubMed ID: 17402806
[TBL] [Abstract][Full Text] [Related]
13. Health care outcomes case study: Febrile neutropenia.
Holdsworth MT; Duncan MH
Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S15-8. PubMed ID: 8846241
[TBL] [Abstract][Full Text] [Related]
14. Pegfilgrastim.
Willis F; Pettengell R
Expert Opin Biol Ther; 2002 Dec; 2(8):985-92. PubMed ID: 12517276
[TBL] [Abstract][Full Text] [Related]
15. The clinical utility of granulocyte colony-stimulating factor: early achievements and future promise.
Morstyn G; Foote M; Perkins D; Vincent M
Stem Cells; 1994; 12 Suppl 1():213-27; discussion 227-8. PubMed ID: 7535147
[TBL] [Abstract][Full Text] [Related]
16. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia.
Aapro M; Cornes P; Abraham I
J Oncol Pharm Pract; 2012 Jun; 18(2):171-9. PubMed ID: 21610020
[TBL] [Abstract][Full Text] [Related]
17. Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings.
Dunn CJ; Goa KL
Drugs; 2000 Mar; 59(3):681-717. PubMed ID: 10776839
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic administration of granulocyte colony-stimulating factor (filgrastim) after conventional chemotherapy in children with cancer.
Riikonen P; Rahiala J; Salonvaara M; Perkkiö M
Stem Cells; 1995 May; 13(3):289-94. PubMed ID: 7542114
[TBL] [Abstract][Full Text] [Related]
19. [Prevention and treatment of febrile neutropenia].
Montemurro F; Gallicchio M; Aglietta M
Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
[TBL] [Abstract][Full Text] [Related]
20. Recombinant granulocyte colony-stimulating factor (rG-CSF): pharmacoeconomic considerations in chemotherapy-induced neutropenia.
Faulds D; Lewis NJ; Milne RJ
Pharmacoeconomics; 1992 Apr; 1(4):231-49. PubMed ID: 10147015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
